Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT02670083) enrolled 813 people in total — 409 received a placebo and 404 received crenezumab, an investigational drug being studied in relation to Alzheimer's disease. The trial ran for approximately two years (105 weeks) and was measuring changes in memory, thinking, and daily functioning over that time using several standard assessment tools. The reported data shows that the trial was closed early due to a lack of efficacy, and results were only counted up to 29 January 2019 to avoid any bias from that early closure. Of the 813 people who started, only 173 completed the trial (88 in the placebo group and 85 in the crenezumab group). The reported data shows the following changes in scores from the start of the trial to week 105. On the primary measure — the CDR-SB scale, which rates memory and daily functioning on a scale of 0 to 18 (higher scores mean greater difficulty) — the placebo group's score changed by an average of 3.42 points, while the crenezumab group's score changed by an average of 3.59 points. On two cognitive (thinking and memory) tests called the ADAS-Cog-13 and ADAS-Cog-11 (where higher scores mean more difficulty), the reported average changes were 9.55 and 8.43 points respectively for the placebo group, and 9.82 and 8.53 points for the crenezumab group. On a separate dementia severity rating (CDR Global Score, scale 0–3), the placebo group changed by an average of 0.55 and the crenezumab group by 0.50. On the MMSE thinking test (scale 0–30, where higher is better), both groups' scores declined — by an average of 4.63 points in the placebo group and 4.96 points in the crenezumab group. Finally, on the daily activities scale (ADCS-ADL, scale 0–78, where higher is better), both groups' scores declined — by an average of 11.51 points in the placebo group and 13.39 points in the crenezumab group. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 41537338) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Alzheimer's Disease Trial, Terminated
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- You weigh between 40 and 120 kilograms (about 88 to 265 pounds)
- You have someone in your life (like a family member or close friend) who sees you regularly, can accurately describe your memory and daily functioning, is willing to attend clinic visits and sign a consent form, and has good enough memory themselves to report on your condition
- You are fluent in the language used for the tests at the study site
- You have good enough vision and hearing to complete memory and thinking tests (glasses and hearing aids are allowed)
- Testing of your spinal fluid or a brain scan shows signs of Alzheimer's-related changes (specifically, a protein called amyloid)
- Memory tests done at or shortly before your screening visit show abnormal memory function (based on specific test scores — confirm with trial site)
- Your score on a standard memory and thinking test (called the MMSE) is 22 or higher, and a doctor's rating of your daily functioning falls within a specific range (called CDR-GS 0.5 or 1.0)
- A doctor has diagnosed you with probable Alzheimer's disease or early-stage memory impairment consistent with Alzheimer's, following recognised medical guidelines
- If you are already taking medication for Alzheimer's symptoms, your dose has stayed the same for at least 3 months before the screening visit
- You have completed at least 6 years of formal schooling after the age of 5
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- You have a condition other than Alzheimer's that affects memory or thinking, such as another type of dementia, stroke, brain injury, certain autoimmune diseases (like multiple sclerosis), or a past infection that affected the brain
- You have a history of serious mental illness, such as schizophrenia, or depression that is not currently under control
- The study doctor has concerns that you may be at risk of harming yourself
- Your MRI brain scan shows certain abnormalities (such as signs of blood vessel problems or a past stroke), you are unable to tolerate an MRI scan, or you have a medical reason you cannot have an MRI
- You have an unstable or serious heart, kidney, or liver condition (for example, a recent heart attack)
- Your blood pressure is not well controlled
- A blood test at screening shows your blood sugar control is poor (HbA1c above 8%)
- Your veins make it difficult to take blood samples
- You have a history of cancer, unless it is considered fully treated/cured or you are not currently receiving cancer treatment or radiotherapy
- You have had a serious allergic reaction (including anaphylaxis) to certain types of antibody-based medicines in the past (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
If you need support right now
This page includes language about suicide and self-harm, because that is how the trial's eligibility criteria are written. If reading it has been hard, you do not have to keep going. The services below are free, confidential, and answered by people trained for exactly this.
If you or someone else is in immediate danger, call 000.
- Lifeline — 24/7 crisis support: 13 11 14
- Suicide Call Back Service — 24/7 counselling: 1300 659 467
- 13YARN — 24/7, for Aboriginal and Torres Strait Islander people: 13 92 76
- Beyond Blue — 24/7 mental health support: 1300 22 4636
- Emergency: 000
Outside Australia? The numbers above are Australian and will not work from overseas. Find a Helpline is a free directory of crisis lines in over 130 countries, run by ThroughLine with the International Association for Suicide Prevention. If you are in immediate danger, call your local emergency number.
Voxsanity is not a crisis service, and nothing on this page is medical advice. More Australian services are listed on our support lines page.
Trial contact details on record
Principal Investigator: Clinical Trials, Hoffmann-La Roche
Australian sites
This trial is not accepting new participants. These are the contact details ClinicalTrials.gov holds for it, kept here for reference. They are not an invitation to enrol, and the sites listed may no longer be running this trial.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial was run
These are the locations recorded on the registry, including 4 in Australia. They are a historical record: this trial is not enrolling, so they are not places you can join it.
Primary endpoints
Change From Baseline to Week 105 in Clinical Dementia Rating-Sum of Boxes (CDR-SB) Score
Other options
Data last synced from ClinicalTrials.gov: 10 August 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.